Royalty Report: Drugs, Ophthalmological, Pharmaceuticals – Collection: 155

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Ophthalmological
  • Pharmaceuticals
  • Disease
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 155

License Grant
The Licensor desires to grant to the Licensee, an exclusive worldwide License to all of the Licensor's rights in and to N-Chlorotaurine for the development and commercialization of ophthalmic pharmaceutical products for use in humans in accordance with the terms of the agreement.
License Property
The Licensor has exclusively licensed rights to N-Chlorotaurine, a chemical substance produced within the body by white blood cells during an inflammatory reaction (“N-Chlorotaurine”).

N-Chlorotaurine could be developed into an efficacious treatment for conjunctivitis and other related ocular conditions.

Field of Use
Field of Use means the treatment of ophthalmic diseases or infection, such as but not limited to, viral conjunctivitis, bacterial conjunctivitis and herpetic keratitis.

IPSCIO Record ID: 5899

License Grant
The Licensee signed an exclusive licensing Agreement with the Licensor for the U.S. and Canadian commercialization of AzaSite (1.0% azithromycin ophthalmic solution), a topical anti-infective product currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of bacterial conjunctivitis. Under the terms of the Agreement, the Licensee has acquired from Licensor exclusive rights to commercialize AzaSite for ocular infections in the United States and Canada.
License Property
AzaSite contains the drug azithromycin, a broad-spectrum antibiotic, formulated with DuraSite®, InSite Vision's patented drug-delivery vehicle.

IPSCIO Record ID: 1449

License Grant
The Company has license agreements with an undisclosed former director wherein the Company has acquired rights to develop and commercialize certain research technologies.

The sale and assignment of Lotemax and Alrex.

License Property
Lotemax and Alrex are the trade names of drug products in the form of eye drop suspensions in which the active compound is loteprednol etabonate ('LE').

Lotemax is a topical, site-specific steroid that is used to treat steroid responsive inflammatory eye conditions. The prescription eye drop is also used for post-operative eye inflammations such as experienced following cataract surgery. The novel chemical structure of Lotemax allows it to be predictably transformed by enzymes in the eye to an inactive metabolite, thereby increasing its safety profile.

Alrex is a specially developed formula of loteprednol etabonate that is used in the treatment of ophthalmic allergies. Alrex is indicated for the treatment of seasonal allergic conjunctivitis, an inflammation of the eye usually caused by pollens. Seasonal allergic conjunctivitis produces itching, tearing, redness and swelling in the conjunctiva, the membrane that covers the inside of the eyelid and the white part of the eye.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.